Clinical Trials Logo

Meibomian Gland Dysfunction clinical trials

View clinical trials related to Meibomian Gland Dysfunction.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04667871 Withdrawn - Clinical trials for Meibomian Gland Dysfunction

Effect of Cataract Hyperemulsification Surgery on Meibomian Gland Morphology and Function

Start date: August 1, 2017
Phase:
Study type: Observational

50 participants at Eye Hospital of Wenzhou Medical University during August, 2017 to July, 2020 will be enrolled in this study. To study the effect of cataract supermammary surgery on the morphology and function of meibomian glands

NCT ID: NCT03788486 Withdrawn - Clinical trials for Meibomian Gland Dysfunction

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

Start date: February 12, 2019
Phase: N/A
Study type: Interventional

This study will test the efficacy and safety of application of LED light to meibomian glands in upper and lower eyelids in eyes of patients suffering with meibomian gland disease.

NCT ID: NCT02894658 Withdrawn - Clinical trials for Meibomian Gland Dysfunction

Lipiflow Versus Warm Compresses in Parkinson's Disease

Start date: August 2016
Phase: N/A
Study type: Interventional

The LipiFlow System (TearScience, Morrisville, NC) is an in-office FDA approved treatment for meibomian gland dysfunction. It relieves meibomian gland obstruction through the use of heat and pulsatile pressure. A recent study has observed that a single treatment with the LipiFlow system can decrease dry eye symptoms and objective findings of meibomian gland dysfunction for 1 year. We aim to see if the Lipiflow System will be beneficial in patients with Parkinsons disease who may have difficulty performing normal meibomian gland dysfunction treatment.

NCT ID: NCT02735681 Withdrawn - Clinical trials for Meibomian Gland Dysfunction

Effect of Meibomian Gland Probing on Ocular Surface in Ocular Rosacea

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Meibomian glands (MG) are modified sebaceous glands associated with the tarsus (collagenous structural component) of the upper and lower eyelids. Meibomian glands produce lipid-based secretions which are an integral and stabilizing part of the tear film. In blepharitis and ocular rosacea (two known causes of obstructive meibomian gland dysfunction (o-MGD), inflammation of the lid margins causes blockage of the meibomian gland orifices, changes in glandular secretions, and dropout of the glands themselves. This limits the production, secretion, and quality of meibum. With less oil in the tear film, the aqueous portion of tears is not stable and evaporates quickly which leads to dry eye.

NCT ID: NCT01917539 Withdrawn - Dry Eye Syndrome Clinical Trials

Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome

Start date: June 2013
Phase: N/A
Study type: Interventional

Our primary aim is to determine whether pulsed light therapy (PLT) is effective in reducing symptoms and improving clinical stigmata of dry eye syndrome (DES) associated with meibomian gland dysfunction (MGD) in patients with facial rosacea (which includes ocular rosacea). The uses of PLT are for treatment of rosacea, hair removal, pigmented lesions, and skin telangiectasias. The risks include the potential for transient sunburn-like sensations (i.e. redness, burning sensation) and particularly if not used properly, the potential to cause burns, blistering, scarring, and pigmentary changes.

NCT ID: NCT01797107 Withdrawn - Clinical trials for Meibomian Gland Dysfunction

Study to Determine the Effect of Azasite on Corneal Surface Irregularity

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of Azasite on patients with corneal surface irregularity (meibomian gland dysfunction).